Chitosan/GP Hydrogel Formulations for Sustained VLP Delivery

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Existing formulations for Cowpea mosaic virus (CPMV) require repeat administration for effective vaccine efficacy and cancer immunotherapy, with limited success due to technical challenges in slow-release formulations.

Innovation Solution

Formulations comprising CPMV nanoparticles in chitosan/GP hydrogels provide a slow-release mechanism, allowing for a single-dose vaccine candidate and long-lasting plant virus-based nanomedicines by incorporating VLPs derived from plant viruses like CCMV, CPMV, or PhMV, with therapeutic peptides, encapsulating additional agents, and conjugating peptides via NHS-activated esters.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If repeat administration is used to achieve potent efficacy, then vaccine efficacy and cancer immunotherapy are improved, but device complexity and administration burden increase

Engineering Contradiction:

Improvevaccine efficacyVSAvoidadministration frequency

Core Design Contradiction:

ReliabilityVSDevice complexity

Solution Approach 1:

The patent applies preliminary action by pre-formulating CPMV VLPs within chitosan/GP hydrogels before administration. The hydrogel matrix is prepared in advance with embedded VLPs, creating a ready-to-deploy formulation that releases VLPs continuously over time, eliminating the need for repeated administrations to maintain efficacy.

Inventive Principle:

Principle #10Preliminary action

Solution Approach 2:

The patent implements continuity of useful action through the slow-release mechanism of the hydrogel formulation. The chitosan/GP hydrogel matrix continuously releases CPMV VLPs over extended periods, maintaining therapeutic efficacy without interruption and eliminating the need for repeat administrations to sustain the immune response.

Inventive Principle:

Principle #20Continuity of useful action

2Productivity

If slow-release formulations are developed, then administration frequency is reduced, but manufacturing precision and formulation stability become more difficult to control

Engineering Contradiction:

Improveadministration frequencyVSAvoidrelease rate control

Core Design Contradiction:

ProductivityVSManufacturing precision

Solution Approach 1:

The patent applies parameter changes by systematically varying chitosan molecular weight (250-1500 kDa), GP concentration (2.5-10%), and VLP concentration (0.1-7 mg/ml) to optimize the release profile. These parameter adjustments allow precise control over the slow-release characteristics while maintaining manufacturing feasibility and formulation stability.

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The patent utilizes composite materials by combining chitosan polymer with GP to form a hydrogel matrix that encapsulates CPMV VLPs. This composite structure provides both the slow-release functionality and the structural integrity needed for stable manufacturing, resolving the contradiction between controlled release and manufacturing precision.

Inventive Principle:

Principle #40Composite materials

3Reliability

If VLP concentration is increased to enhance immunogenicity, then therapeutic efficacy is improved, but formulation stability and particle integrity may be compromised

Engineering Contradiction:

ImproveimmunogenicityVSAvoidparticle integrity

Core Design Contradiction:

ReliabilityVSStability of the object's composition

Solution Approach 1:

The patent applies the intermediary principle by using the chitosan/GP hydrogel matrix as a protective medium between the VLPs and the external environment. This hydrogel intermediary protects VLP structural integrity even at high concentrations (0.1-7 mg/ml), preventing aggregation and degradation while maintaining enhanced immunogenicity.

Inventive Principle:

Principle #24Intermediary (Mediator)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The formulations achieve sustained release of biologically active VLPs over months, inducing potent immune responses and therapeutic effects, including cancer treatment and immune response against pathogens like SARS-CoV-2, with enhanced tissue residence and immunogenicity.

Implementation Method 1

Formulations comprising CPMV nanoparticles in chitosan/GP hydrogels provide a slow-release mechanism

Methodology Applied

Scientific EffectDiffusion: Diffusion

Implementation Method 2

chitosan/GP hydrogels provide a slow-release mechanism, allowing for a single-dose vaccine candidate

Methodology Applied

Scientific EffectHydrogel degradation: Decomposition (biological)

Implementation Method 3

conjugating peptides via NHS-activated esters

Methodology Applied

Scientific EffectChemical bonding: Chemical Bonding

Data Source

PatentUS20250213717A1Hydrogel formulations for VLP therapeutics

Publication Date: 2025.07.03 RGT UNIV OF CALIFORNIA

AI summary

Formulations for improved delivery of therapeutic virus-like particles containing therapeutic peptides are provided. Method for making the formulations and use thereof, are further provided.